ChIPAb+ LSD1 (KDM1A) Antibody – ChIP Validated Antibody and Primer Set

Descrição detalhada : LSD1 (lysine specific demethylase 1), also known as BHC110, is a histone demethylase that specifically demethylates Lys4 of histone H3, a specific tag for epigenetic transcriptional activation, thereby acting as a corepressor. LSD1 acts by oxidizing the substrate by FAD to generate the corresponding imine that is subsequently hydrolyzed. LSD1 demethylates both mono- and tri-methylted Lys4 of histone H3, and may play a role in the repression of neuronal genes. Alone, it is unable to demethylate H3 Lys4 on nucleosomes and requires the presence of RCOR1/CoREST to achieve such activity. LSD1 may also demethylate Lys9 of histone H3, a specific tag for epigenetic transcriptional repression, thereby leading to derepression of androgen receptor target genes., All ChIPAb+ antibodies are individually validated for chromatin precipitation, every lot, every time. Each ChIPAb+ antibody set includes control primers (tested every lot by qPCR) to biologically validate your IP results in a locus-specific context. The qPCR protocol and primer sequences are provided, allowing researchers to validate ChIP protocols when using our antibody in their chromatin context. Each set also includes a negative control antibody to ensure specificity of the ChIP reaction. The ChIPAb+ LSD1 (KDM1A) set includes a LSD1 antibody, a Normal rabbit IgG and positive control primers which amplify a 85bp human prostate-specific antigen enhancer region. The LSD1 antibody and negative control IgG are supplied in a scalable "per ChIP" reaction size and can be used to functionally validate the precipitation of LSD1 associated chromatin.
Sinónimos : Lysine-specific histone demethylase 1A, BRAF35-HDAC complex protein BHC110, Flavin-containing amine oxidase domain-containing protein 2
Armazenamento : -20°C
Embalagem : 1X1EA